Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
28/04/2026 07:12
April 28 (Reuters) - Xspray Pharma publ AB XSPRAY.ST: Q1 PRETAX PROFIT SEK -35.38 MILLION Q1 ADJUSTED FREE CASH FLOW SEK -30.676 MILLION Q1 REVENUE SEK 0 Q1 ADJUSTED EPS SEK -0.85 XSPRAY'S PLAN TO LAUNCH IN U.S. DURING SECOND HALF OF 2026. WELL PREPARED FOR A DUAL LAUNCH OF DASYNOC® AND NILOPKI® IN AUTUMN OF 2026. Source text: ID:nMFNb1mrH0 Further company coverage: XSPRAY.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Xspray Pharma publ AB
See all newsBrief: Xspray Pharma Gets CRL From FDA
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003